Trials / Completed
CompletedNCT01315275
A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 394 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-03-15
- Last updated
- 2017-02-23
Locations
43 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01315275. Inclusion in this directory is not an endorsement.